ESMO 2017

Area: Oncology

Location: Madrid, Spain

Date: September 8 to September 12

Description:

European Society for Medical Oncology Conference.


Search in Scientific Content:
Date
Filters:
Second lin...
4:57

Second line therapy – current strategies and clinical management

Presenter: Enrique Grande
Oncology
Therapeuti
12:41

Therapeutic options for the patient beyond 2nd line in mCRC

Presenter: Alfredo Carrato
Oncology
Optimal ma
6:24

Optimal management of mCRC: From complexity to clarity

Presenter: Dan Aderka
Oncology
Biosimilar
4:50

Biosimilars for Oncologists: what you need to know

Presenter: Fernando de Mora Perez
Oncology
Researchin
8:20

Researching the Potential of Checkpoint Inhibitors in HCC Expect the unexpected

Presenter: Ignacio Melero
Oncology
Putting th
3:53

Putting the patient fiPutting the patient firstrst

Presenter: Geoffrey Henning
Oncology
Treatment ...
5:36

Treatment Decisions for HR+, HER2– Advanced Breast Cancer

Presenter: Olivia Pagani
Oncology
Clinical E
6:31

Clinical Evidence of Biosimilar Trastuzumab

Presenter: Justin Stebbing
Oncology
Biosimilar
5:45

Biosimilar in Oncology: Yesterday, Today and a Look Ahead: Welcome and Introduction

Presenter: Francisco J. Esteva
Oncology
Clinical E
5:010

Clinical Efficacy of Atezolizumab in PD-L1 Subgroups Defined by SP142 and 22C3 IHC Assays in 2L+ NSCLC: Results From the Randomized OAK Study (ROCHE )/ Treating unresectable malignant pleural mesothelioma: current options and future outlook 2.

Presenter: Shirish Madhav Gadgeel
Oncology
Clinical E
3:21

Clinical Efficacy of Atezolizumab in PD-L1 Subgroups Defined by SP142 and 22C3 IHC Assays in 2L+ NSCLC: Results From the Randomized OAK Study (ROCHE )/ Treating unresectable malignant pleural mesothelioma: current options and future outlook 1.

Presenter: Shirish Madhav Gadgeel
Oncology
Can PARP i
5:38

Can PARP inhibitors offer benefit for all patients with platinum-sensitive ovarian cancer?

Presenter: Sven Mahner
Oncology
ESMO guide
4:48

ESMO guideline: supportive care, nutrition, cancer anorexia & cachexia syndrome

Presenter: Henk van Halteren
Oncology
A look to
12:41

A look to the future: How are real-world research initiatives evolving?

Presenter: Frank Griesinger
Oncology
The burden
5:35

The burden of CAT: acknowledging the risk

Presenter: Anthony Maraveyas
Oncology
Optimal tr
7:45

Optimal treatment sequencing in mCRC + Discussion

Presenter: Dirk Arnold
Oncology

ELCC 2022

2022-03-30 - 2022-04-02
Online, Virtual

SABCS 2021

2021-12-07 - 2021-12-10
Online, Virtual

ESMO 2021

2021-09-17 - 2021-09-21
Online, Virtual

ASCO 2021

2021-06-04 - 2021-06-08
Online, Virtual

St. Gallen BCC 2021

2021-03-17 - 2021-03-21
Online, Virtual

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain